Literature DB >> 28052266

Development of a Normative Database for Multifocal Electroretinography in the Context of a Multicenter Clinical Trial.

Sílvia Simão1, Miguel Ângelo Costa, Jennifer K Sun, José Cunha-Vaz, Rafael Simó.   

Abstract

PURPOSE: The aim of this study is to present the largest normative database using multifocal electroretinography (mfERG) in the context of a multicenter clinical trial.
METHODS: This investigational study included 156 eyes from 78 Caucasian subjects aged 45-70 years without known ophthalmic disease or diabetes mellitus; the subjects were recruited from 11 clinical sites in the setting of the EUROCONDOR project. Standardized mfERG acquisition (103 hexagons per eye) was established based on the International Society of Clinical Electrophysiology in Vision. At least one technician per site received both specialized training and certification. The main variables that could have influenced the results were considered in the analyses.
RESULTS: The normative database was based on 111 eyes. The overall mean P1-implicit time (IT) was 33.94 ± 1.70 ms, and the mean P1 amplitude was 30.58 ± 5.20 nV/deg2. Age and gender were independently related to predictors of P1-IT but not of P1 amplitude. The responses that were averaged for the 6 rings showed a longer P1-IT time in the fovea, decreasing progressively to the parafovea and perifovea. By contrast, P1 amplitude values sharply decreased with retinal eccentricity.
CONCLUSIONS: This normative database can be used as a comparative index of expected normal values in the clinical setting and for examining the effect of studies testing neuroprotective agents.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28052266     DOI: 10.1159/000450958

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  5 in total

1.  Fundus motion during mfERG testing.

Authors:  Jennyffer D Smith; Allison Jussel; Rachel Wang; Daniel R Coates; Wendy W Harrison
Journal:  Doc Ophthalmol       Date:  2021-03-13       Impact factor: 2.379

2.  The Ganglion Cell-Inner Plexiform Layer Thickness/Vessel Density of Superficial Vascular Plexus Ratio According to the Progression of Diabetic Retinopathy.

Authors:  Jae-Yun Sung; Min-Woo Lee; Hyung-Bin Lim; Cheon-Kuk Ryu; Hwa-Young Yu; Jung-Yeul Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

3.  The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial.

Authors:  Cristina Hernández; Massimo Porta; Francesco Bandello; Jakob Grauslund; Simon P Harding; Stephen J Aldington; Catherine Egan; Ulrik Frydkjaer-Olsen; José García-Arumí; Jonathan Gibson; Gabriele E Lang; Rosangela Lattanzio; Pascale Massin; Edoardo Midena; Berta Ponsati; Luísa Ribeiro; Peter Scanlon; José Cunha-Vaz; Rafael Simó
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

Review 4.  Neurodegeneration in diabetic retinopathy: does it really matter?

Authors:  Rafael Simó; Alan W Stitt; Thomas W Gardner
Journal:  Diabetologia       Date:  2018-07-20       Impact factor: 10.122

5.  Assessment of Inner Retinal Layers and Choroidal Thickness in Type 1 Diabetes Mellitus: A Cross-Sectional Study.

Authors:  Marc Carbonell; Núria Alonso; Esmeralda Castelblanco; Jordi Real; Anna Ramírez-Morros; Rafael Simó; Cristina Hernández; Carme Jurjo; Alícia Traveset; Xavier Valldeperas; Dídac Mauricio
Journal:  J Clin Med       Date:  2019-09-08       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.